ALBANY, N.Y., April 22, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue first quarter financial results before the opening of the market on Tuesday, May 6, 2014.  Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10:00 a.m. ET.

The conference call can be accessed by dialing 888-438-5524 (domestic calls) or 719-325-2448 (international calls) at 9:50 a.m. ET and entering passcode 8361277.  The audio webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com.  Replays of the audio webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 22 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI

Copyright 2014 PR Newswire

Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Albany Molecular Research, Inc. Charts.
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Albany Molecular Research, Inc. Charts.